Physician profile
Mark C Oveson
NPI 1417974098
$1,894.23
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $511 · 2021: $633 · 2022: $354 · 2023: $54.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $54.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $54.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $465.63 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.39 | 2019-2023 | Jardiance, Synjardy, Trijardy Xr |
| Astrazeneca Pharmaceuticals Lp | $273.74 | 2019-2021 | |
| Lilly USA, LLC | $147.96 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $90.00 | 2019-2021 | |
| Allergan, INC. | $79.71 | 2019-2020 | |
| Abbvie INC. | $70.14 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $67.45 | 2019-2020 | |
| Dexcom, INC. | $62.78 | 2021-2022 | |
| Medtronic Minimed, INC. | $33.39 | 2020 | |
| Nestle Healthcare Nutrition INC. | $31.60 | 2020-2021 | |
| Pfizer INC. | $30.54 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $29.84 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.83 | 2022 | |
| Mylan Specialty L.P. | $26.62 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19.72 | 2019 | |
| Celgene Corporation | $18.18 | 2019 | |
| Sanofi Pasteur INC. | $15.34 | 2019 | |
| Organon LLC | $15.06 | 2022 | |
| Cranial Technologies, INC | $14.18 | 2020 | |
| Novartis Pharmaceuticals Corporation | $12.52 | 2022 | |
| Medtronic, INC. | $12.37 | 2022 | |
| Insulet Corporation | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Oveson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.